Figure 1.

MBD2 was Overexpressed in CML-BP Patients, and MBD2 Expression was Deleted by CRISPR/Cas9-mediated Gene Disruption in K562 Cells. (A) Normal BM samples were collected from healthy volunteer donors as healthy controls. The mRNA levels of MBD2 were detected in CML-CP, CML-BP patients and healthy controls via qRT-PCR. (B, C) The cell model of homozygous deletion mutation of MBD2 was constructed by using the CRISPR/Cas9 gene editing system in K562 cells. QRT-PCR (B) and Western blotting (C) were used to measure the different expression levels of MBD2 in K562 (MBD2 WT vs. MBD2 KO) cells. (D) The representative pictures of immunofluorescence in MBD2 WT and MBD2 KO cells, which demonstrate the expression level of MBD2. Blue, DAPI; Red, MBD2; magnification of x400. *P < 0.05 by Student's t-test.